Delving into the Latest Updates on Beijing Inno Medicine Co., Ltd. with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Cardiovascular Diseases

Other Diseases

Small molecule drug

siRNA

Contrast agent

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	2
Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1
Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	3
Contrast agent	1
siRNA	1

Top 5 Target	Count

DNA x Top II	1
CD44 x HMG-CoA reductase	1

This study consists of two parts. The SAD and MAD of part I are a randomized, double-blind, placebo-controlled, single and multiple ascending dose study in healthy adult subjects. The MAD expansion cohort of part I is single arm and multipal ascending dose in heallthy subjects. Part II (phase Ib/IIa) is a multicenter, randomized, controlled, open label, multiple ascending dose study in patients with coronary atherosclerosis.

Start Date08 Oct 2023

Sponsor / Collaborator

Beijing Inno Medicine Co., Ltd.

CTR20232962 / RecruitingPhase 1

一项评价YN001在中国健康受试者中单次和多次给药及冠状动脉粥样硬化患者中多次给药的安全性、耐受性、药代动力学和初步疗效特征的剂量递增I期临床试验

[Translation] A Phase I dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy characteristics of single and multiple doses of YN001 in healthy Chinese subjects and multiple doses in patients with coronary atherosclerosis

Ia期主要目的：在中国健康受试者中，评估YN001单次和多次静脉给药剂量递增的安全性和耐受性及药代动力学特征。次要目的：在中国健康受试者中，评估YN001单次静脉给药剂量递增对QT/QTc间期的影响及多次静脉给药剂量递增的免疫原性。 Ib期主要目的：在冠状动脉粥样硬化患者中，评估YN001多次静脉给药剂量递增的安全性和耐受性；次要目的：在冠状动脉粥样硬化患者中，评估YN001多次静脉给药剂量递增的药代动力学特征、初步疗效、免疫原性和细胞因子变化。

[Translation]

The primary objective of Phase Ia is to evaluate the safety, tolerability and pharmacokinetic characteristics of single and multiple intravenous doses of YN001 in healthy Chinese subjects. Secondary objectives: To evaluate the effects of single intravenous doses of YN001 on the QT/QTc interval and the immunogenicity of multiple intravenous doses in healthy Chinese subjects. The primary objective of Phase Ib is to evaluate the safety and tolerability of multiple intravenous doses of YN001 in patients with coronary atherosclerosis; Secondary objectives: To evaluate the pharmacokinetic characteristics, preliminary efficacy, immunogenicity and cytokine changes of multiple intravenous doses of YN001 in patients with coronary atherosclerosis.

Start Date08 Oct 2023

Sponsor / Collaborator

Beijing Inno Medicine Co., Ltd.

NCT05635084 / RecruitingPhase 1

A First-in-human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered YN001 in Healthy Subjects

This will be a single center, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study in healthy adult subjects.

Start Date16 Dec 2022

Sponsor / Collaborator

Beijing Inno Medicine Co., Ltd.

100 Clinical Results associated with Beijing Inno Medicine Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Inno Medicine Co., Ltd.

Login to view more data

100 Deals associated with Beijing Inno Medicine Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Inno Medicine Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 11 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

3

Preclinical

Phase 2 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

YN-001 ( CD44 x HMG-CoA reductase )	Atherosclerosis More	Phase 2 Clinical
Epirubicin Hydrochloride ( DNA x Top II )	Malignant glioma of brain More	Preclinical
YN-002 (Inno Medicine)	Contrast agents More	Preclinical
YN001a	Rheumatoid Arthritis More	Preclinical
YN-005	-	Discovery